Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide

Abaloparatide (ABL) is a 34-amino acid peptide designed to be a selective activator of the parathyroid hormone receptor type 1 signaling pathway. In the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE), subcutaneous ABL reduced the risk of new vertebral, nonvertebral, clinical, and maj...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Calcif Tissue Int
Päätekijät: Reginster, Jean-Yves, Hattersley, Gary, Williams, Gregory C., Hu, Ming-yi, Fitzpatrick, Lorraine A., Lewiecki, E. Michael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2018
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182596/
https://ncbi.nlm.nih.gov/pubmed/29951742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00223-018-0450-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia